Status:
UNKNOWN
Neural Mechanisms and Efficacy of Dual Neurotechnology-aided Mirror Therapy in Chronic Stroke: Neural and Motor Plasticity, Movement Performance, Daily Function, and Quality of Life
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Cerebrovascular Accident
Eligibility:
All Genders
35-85 years
Phase:
NA
Brief Summary
Mirror therapy (MT) has been demonstrated, in terms of neuroplasticity, to improve sensorimotor function of paretic upper extremity (UE) in chronic stroke patients. Central and peripheral electrical s...
Eligibility Criteria
Inclusion
- sustained a unilateral stroke with onset ≥ 3 months (Figlewski et al., 2017);
- UE Fugl-Meyer assessment (UE-FMA) score between 18 and 56 indicating mild to moderate mild motor severity (Menezes et al., 2018; Woodbury, Velozo, Richards, \& Duncan, 2013);
- aged 35 to 85 years old; and
- able to follow instructions and perform the tasks (Mini Mental State Examination ≥24).
Exclusion
- with excessive spasticity or joint contracture of the paretic UE;
- enrolled in other rehabilitation experiments or drug studies;
- with additional neurological or psychological disorders other than stroke;
- having received Botulinum toxin injections 3 months before enrollment;
- having unstable cardiovascular status such as uncontrolled hypertension or New York Heart Association (NYHA) Class III/IV heart failure;
- having contradictions to tDCS including a history of epilepsy, migraine headache, uncontrolled medical status, being pregnant, having a pacemaker, or metal implanted in their head or body (not including dental fillings or hardware)(Meeker et al., 2019; Rossi, Hallett, Rossini, Pascual-Leone, \& Group, 2009);
- having a history of drug or alcohol abuse, dermatosis preventing tDCS from being applied, brain tumor, brain injury, arteriovenous malformation, other brain diseases (such as intracranial hypertension or cerebral edema), or are not suitable for using tDCS by the physician's assessment; and (8) having existence of skin rash, allergy or wounds at the locations where stimulation electrodes would be placed.
Key Trial Info
Start Date :
April 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT04326205
Start Date
April 14 2021
End Date
July 31 2023
Last Update
May 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan, Taiwan, 333